Drug Security Forum

The Pharmaceutical Industry in Russia: Results of the Reset

14 Jun , 10:00–11:30
‘Ensuring Drug Security’ Russian Pharmaceutical Forum
Pavilion G, conference hall G5

During the period of 2020-22, the domestic pharmaceutical industry proved its responsibility and high level of expertise. The pandemic forced the industry to mobilize its resources and to quickly seek solutions in the face of unprecedented challenges. According to statistics from 2022, domestically manufactured medicines make up 82% of the 810 items identified as International Nonproprietary Names on the list of vital and essential drugs (VED), while more than 53% of the drugs have already gone through the full drug development process. The share of domestically produced drugs in government procurement is more than 80%; the production volume of medicines has increased by more than 10%, and the production of pharmaceutical substances has increased by more than 7%. A total of 940 new domestically manufactured medicines have been registered. The industry’s achievements are, among other things, the result of joint work based on the implementation of the Pharma 2020 strategy. What trends and current challenges are included in the Pharma-2030 strategy, and is the Russian pharmaceutical industry ready to accept these challenges? What specific steps need to be taken to strengthen the domestic pharmaceutical industry on the threshold of the implementation of new plans? How ambitious and feasible are the stated objectives?

Aleksey Kedrin, Chairman of the Board, Association of Pharmaceutical Manufacturers of the Eurasian Economic Union (EAEU)

Sergey Glagolev, Deputy Minister of Health of the Russian Federation
Dmitry Zaitsev, General Director, Pharmstandard
Dmitry Kudlay, Vice President for the Implementation of New Medical Technologies, Generium
Timofey Nizhegorodtsev, Deputy Head, Federal Antimonopoly Service of the Russian Federation (online)
Ekaterina Priezzheva, Deputy Minister of Industry and Trade of the Russian Federation
Aleksandr Semenov, President, Active Component
Lyudmila Scherbakova, Co-Founder, Chairman of the Board of Directors, Velpharm